Tislelizumab plus chemotherapy improves overall survival in advanced gastric/GEJ adenocarcinoma

Results from the RATIONALE-305 trial were published 25 October 2026.

Stands on 1 first-party reading of PubMed and ClinicalTrials.gov, not reporting.

A randomized controlled trial finding tislelizumab plus chemotherapy improved overall survival in advanced gastric or gastroesophageal junction adenocarcinoma was published 25 October 2026, per PubMed and ClinicalTrials.gov records.^[1] The analysis examined the patient subgroup with PD-L1 tumor area positivity score ≥ 5%. 475 patients were included in this subgroup. 238 patients received tislelizumab plus chemotherapy. 237 patients received placebo plus chemotherapy. Authors reported the overall survival benefit was observed both in this defined subgroup and across all enrolled trial patients. The paper appears in Quality of Life Research. It carries PubMed identifier 42927580.

Proof1 source · 1 publisher · signed

What this stands on

"Prognostic associations between patient-reported outcomes and progression-free and overall survival in advanced gastric or gastroesophageal junction adenocarcinoma with PD-L1 TAP score ≥ 5%: results from the RATIONALE-305 trial." published in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation as a randomized controlled trial (PubMed 42927580, doi 10.1007/s11136-026-04416-4). Sample: 238 as stated in the abstract. Results as the a · PubMed and ClinicalTrials.gov, read by the New studies instrument · the fact recordUnited Statesofficial source

Read directly from PubMed and ClinicalTrials.gov, the public registries of published studies and registered trials, not from anyone's report of it.